NCT07014410View on ClinicalTrials.gov

Pyrotinib Combined With Dalpiciclib Combined With Letrozole in ER-positive and HER2-positive Advanced Breast Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

February 1, 2023

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2029

Conditions
Breast Cancer
Interventions
DRUG

pyrotinib dalpiciclib letrozole

ER positive HER2 positive advanced breast cancer patients are given pyrotinib+dalpiciclib+letrozole

Trial Locations (1)

Unknown

RECRUITING

Zhejiang Cancer Hospital, Hangzhou

All Listed Sponsors
lead

Zhejiang Cancer Hospital

OTHER